N/A
N=40
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Retinitis Pigmentosa · AMD
Bottom Line
View on ClinicalTrials.gov: NCT03322930 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S — 7; 20 Participants — p=<0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Rod sensitivity (Diagnostic_test)
- Age
- Pediatric, Adult, Older Adult · 10+ yrs
- Sex
- All
- Sponsor
- Retina Foundation of the Southwest
- Primary completion
- Mar 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rod Sensitivity Within the Central Retina as Measured on the Nidek MP-3S |
7; 20 | <0.05 sig |
Summary
A new fundus-guided microperimeter (MP-3S) has been developed by Nidek, Inc. to track the fundus of the patient and present stimuli in specific anatomically-defined locations. Furthermore, this tracking means that exactly the same locations can be tested on subsequent (follow-up) visits. The investigators will use a method called two-color perimetry to map rod and cone sensitivity on this device. With this technique, the sensitivity difference (blue-red) to chromatic test stimuli can be used to determine whether rods, cones or both photoreceptor systems mediate the threshold at a given location in the macula.
Eligibility Criteria
Inclusion Criteria
- clear media
- diagnosis of RP or non neovascular AMD
- normal volunteers
Exclusion Criteria
- exudative AMD
- other eye diseases that could cause vision loss
- physical ailments that would preclude comfortable testing
- unable to provide informed consent
Data sourced from ClinicalTrials.gov (NCT03322930). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.